This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better compared to crizotinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.

This partially randomized phase II/III trial studies how well cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or liver cancer after surgery. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy after surgery may kill more tumor cells.

Patients will undergo a blood draw for a gene classifier test. Some patients will have their physicians informed of the result, and another group of patients will be randomized to be managed by standard of care. Qualifying patients have incidentally identified lung nodules assessed as < 50% risk of cancer.

The purpose of this study is to determine if treating germinomas with chemotherapy followed by a lower dose of radiotherapy (RT) can be as effective as the current standard of care. Specifically, our primary aim is to determine whether 12 Gy whole ventricular irradiation (WVI) and 12 Gy tumor boost would maintain similar efficacy compared to ACNS1123 stratum 2 as measured by event-free survival (EFS) in eligible patients with localized primary central nervous system (CNS) germinoma who present with serum and/or CSF human chorionic gonadotropin-beta (hCGß) = 100 IU/L and normal AFP, and meet complete response (CR) or continued complete response (CCR) criteria following chemotherapy/second-look surgery (Stratum 1). We are attempting to build upon the excellent results of ACNS1123 stratum 2 by reducing the RT dose even further for patients in a CR after chemotherapy.

The purpose of this single-arm phase 2 study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.

We have created a workbook about Lynch Syndrome, a genetic condition that means an individual is at high risk of developing certain cancers, and family testing. It is important that patients with Lynch Syndrome tell their family members about their condition so their family members understand their risks and can be tested for Lynch Syndrome too. We are testing our workbook with a small group of patients with Lynch Syndrome to understand if the workbook is helpful in managing their condition and talking to family members.

To compare disease-free survival (DFS) as assessed by the investigator for high-risk renal cell carcinoma patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone.

Screening tool to collect broader demographic and clinical data. Enhance understanding of site specific and trial specific accrual barriers.

The purpose of this study is to assess how the use of community health-workers for human papillomavirus (HPV) testing influences the number of women living with HIV who get screened for cervical cancer.

Purpose: to establish a Registry of pediatric patients treated with proton radiation therapy. Participants: Patients who are less than or equal to 21 years old at time of treatment start and treated with radiation therapy at one of the participating centers. Procedures (methods): This Proton and Photon Consortium Registry (PPCR) enrolls children treated with radiation therapy to form an expansive description of the pediatric population that receives protons and to better catalogue the benefits of protons, in this cohort. The data will also be used to evaluate practice differences and help facilitate collaborative research across the various radiation centers. The PPCR collects an expanded set of demographic and clinical data that will enhance the practice data that many participating radiation centers already collect in their routine operations. The PPCR has been expanded to include a photon-treated control group, helping to facilitate comparative effectiveness analysis.